Attached files
| file | filename |
|---|---|
| EX-99.1 - PRESS RELEASE DATED MAY 9, 2017 - NAVIDEA BIOPHARMACEUTICALS, INC. | navb_ex99-1.htm |
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE
ACT OF 1934
Date of Report (Date of earliest event reported)
May 9,
2017
|
NAVIDEA BIOPHARMACEUTICALS,
INC.
|
|
(Exact name of registrant as specified in its charter)
|
|
Delaware
|
|
001-35076
|
|
31-1080091
|
|
(State or other jurisdiction
|
|
(Commission
|
|
(IRS Employer
|
|
of incorporation)
|
|
File Number)
|
|
Identification No.)
|
|
5600 Blazer Parkway, Suite 200, Dublin, Ohio
|
|
43017
|
|
(Address of principal executive offices)
|
|
(Zip Code)
|
Registrant's telephone number, including area code
(614) 793-7500
|
|
(Former name or former address, if changed since last
report.)
Check the appropriate box below if the Form 8-K filing is intended
to simultaneously satisfy the filing obligation of the registrant
under any of the following provisions (see General Instruction A.2.
below):
☐
Written
communications pursuant to Rule 425 under the Securities Act (17
CFR 230.425)
☐
Soliciting material pursuant to Rule 14a-12 under the Exchange Act
(17 CFR 240.14a-12)
☐
Pre-commencement communications pursuant to Rule 14d-2(b) under the
Exchange Act (17 CFR 240.14d-2(b))
☐
Pre-commencement communications pursuant to Rule 13e-4(c) under the
Exchange Act (17 CFR 240.13e-4(c))
Item 2.02
Results of Operations and Financial Condition.
On May
9, 2017, Navidea Biopharmaceuticals, Inc. (the
“Company”) issued a press release regarding its
consolidated financial results for the quarter ended March 31,
2017. A copy of the Company’s May 9, 2017 press release is
furnished as Exhibit 99.1 to this Current Report on Form 8-K and is
incorporated herein by reference.
The
information contained in Item 2.02 of this Current Report on Form
8-K, including exhibit 99.1 attached hereto, shall not be treated
as “filed” for purposes of the Securities Exchange Act
of 1934, as amended.
Item 9.01
Financial Statements and Exhibits.
(d)
Exhibits.
|
Exhibit
|
|
|
Number
|
Exhibit Description
|
|
|
|
|
99.1
|
SIGNATURES
Pursuant to the
requirements of the Securities Exchange Act of 1934, the registrant
has duly caused this report to be signed on its behalf by the
undersigned hereunto duly authorized.
|
|
Navidea
Biopharmaceuticals, Inc.
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Date: May 9,
2017
|
By:
|
/s/ Jed
A. Latkin
|
|
|
|
|
Jed A.
Latkin, Chief Operating Officer and
Chief
Financial Officer
|
|
|
|
|
|
|